VIP 6mg

VIP 6mg is suited for research teams investigating VPAC receptor binding dynamics, neuropeptide-mediated cytokine pathway modulation, and neuroimmune signaling interactions in controlled laboratory models. Laboratories examining VIP receptor occupancy across immune cell subtypes, gut mucosal signaling marker expression, or airway-associated neuroimmune pathway activity will find this compound relevant to mechanistic study designs. Research programs investigating gut-brain axis neuropeptide signaling, T-regulatory cell pathway activity, or bronchial smooth muscle receptor dynamics benefit from this compound’s well-characterized 28-amino acid structure. Produced by Elivena in USA GMP-certified facilities, each vial is COA-verified for sequence identity and purity.

VPAC Receptor Pharmacology Studies

VIP supports in-vitro investigation of VPAC1 and VPAC2 receptor binding kinetics, ligand affinity characterization, and receptor subtype selectivity in cell line and primary culture models. Researchers examining cAMP second messenger activity, PKA phosphorylation dynamics, and downstream transcriptional marker expression following VPAC receptor activation use VIP as a primary reference ligand for receptor pharmacology study designs.

Cytokine Network and Immune Signaling Research

Laboratories studying neuropeptide-mediated modulation of cytokine network dynamics use VIP to examine changes in pro- and anti-inflammatory cytokine marker expression in immune cell experimental models. Research designs quantify NF-κB pathway activation status, cytokine transcription factor binding activity, and secreted protein marker levels following VPAC receptor stimulation — contributing to mechanistic understanding of neuropeptide involvement in immune signaling pathway regulation.

Gut Mucosal and Enteric Signaling Pathway Investigation

VIP is studied in gastrointestinal mucosal model systems for its interaction with enteric nervous system signaling pathways and epithelial barrier marker expression. Researchers examining intestinal mucosal receptor distribution, enteric neurotransmission dynamics, and paracellular permeability marker activity utilize VIP to characterize neuropeptide contributions to gut mucosal signaling at a molecular level — without referencing clinical or physiological outcome endpoints.

Airway and Bronchial Smooth Muscle Receptor Research

VIP’s activity at VPAC receptors expressed in bronchial smooth muscle and airway epithelial cell populations makes it relevant for studies examining neuropeptide-mediated smooth muscle receptor signaling, cAMP-dependent relaxation pathway marker activity, and airway immune cell cytokine endpoint quantification in controlled preclinical respiratory models.

Preparation Guidelines Reconstitute lyophilized

VIP 6mg with sterile bacteriostatic water or sterile saline using standard sterile laboratory technique. VIP should be used promptly following reconstitution due to its susceptibility to enzymatic degradation under non-optimized storage conditions. Reconstitution volume should be determined based on the target experimental concentration specified by the study design. Use calibrated laboratory equipment for all preparation and handling steps.

Storage Conditions

Store lyophilized peptide at 2–8°C or -20°C for long-term stability, protected from light and moisture, prior to reconstitution. Following reconstitution, maintain refrigeration at 2–8°C and use within the shortest timeframe consistent with the laboratory protocol to preserve neuropeptide integrity. Lyophilized material does not require cold-chain shipping but should be refrigerated upon receipt. Each Elivena vial is supplied with COA documentation and handling guidance.

USA GMP Manufacturing by Elivena

VIP 6mg is manufactured by Elivena in USA GMP-certified facilities to approximately 99% purity, verified by independent third-party analysis. COA documentation accompanies each vial, confirming the complete 28-amino acid sequence identity, purity grade, and batch consistency. This level of characterization ensures reproducible material for advanced neuropeptide receptor signaling and neuroimmune pathway research.

• CAS: 37221-79-7
• Chemical Formula: C₁₄₇H₂₃₇N₄₃S
• Molecular Weight: 3326.8 g/mol
• Peptide Sequence: HSDAVFTDNYTRLRKQMAVKKYLNSILN
• Synonyms: Vasoactive Intestinal Peptide, Intestinal Peptide, PHM-27
• Shelf life: 24 months from the manufacturing date.

VPAC1 and VPAC2 Receptor Binding Profile

Vasoactive intestinal peptide is a 28-amino acid neuropeptide that binds with high affinity to VPAC1 and VPAC2 G-protein-coupled receptors, both of which are expressed across immune, epithelial, smooth muscle, and neuronal cell populations. This broad receptor distribution makes VIP a relevant model compound for studying neuropeptide-receptor interaction dynamics across multiple tissue system models simultaneously. Binding at VPAC receptors initiates cAMP-dependent intracellular signaling cascades, enabling researchers to examine downstream PKA pathway activity and transcription factor modulation in controlled cell-based assays.

Cytokine Pathway Marker Modulation

VIP is studied for its modulatory effects on pro-inflammatory cytokine expression — including TNF-α, IL-6, and IL-12 — and its association with elevated anti-inflammatory cytokine marker activity such as IL-10 in preclinical immune cell models. Researchers use VIP to examine how VPAC receptor activation influences cytokine transcription factor activity, NF-κB pathway signaling, and MAPK cascade dynamics in macrophage, dendritic cell, and T-lymphocyte experimental systems. These molecular endpoints support detailed mechanistic characterization of neuropeptide-mediated immune signaling pathway behavior.

Neuroimmune Signaling Distribution

VIP’s expression across enteric nervous system, respiratory mucosal tissue, and central nervous system cell populations makes it a relevant research compound for studying neuroimmune signaling dynamics at tissue-system interfaces. Laboratories examining gut-brain axis neuropeptide signaling, airway neuroimmune pathway activity, or lymphoid tissue receptor expression use VIP as a structurally defined reference compound for multi-system receptor interaction studies.

USA GMP Manufacturing by Elivena

VIP 6mg is manufactured by Elivena in USA GMP-certified facilities to approximately 99% purity, verified by independent third-party analysis. COA documentation accompanies each vial, confirming the complete 28-amino acid sequence identity, purity grade, and batch consistency. This level of characterization ensures reproducible material for advanced neuropeptide receptor signaling and neuroimmune pathway research.

VIP binds VPAC1 and VPAC2 G-protein-coupled receptors, initiating Gs-protein-mediated adenylyl cyclase activation and consequent intracellular cAMP elevation. This second messenger activity drives PKA-dependent phosphorylation cascades and downstream transcription factor modulation, which researchers quantify as molecular endpoints in cell-based receptor pharmacology and signaling pathway studies.

VPAC1 and VPAC2 receptors are expressed across enteric nervous system, intestinal mucosal epithelial, bronchial smooth muscle, and airway epithelial cell populations. This broad tissue distribution makes VIP a useful model compound for studying neuropeptide receptor interaction dynamics across multiple tissue system models within the same research program, enabling comparative signaling pathway analysis across cell types.

VIP may be included in combination study designs alongside other neuropeptide or immunomodulatory research compounds to investigate additive or interactive effects on VPAC receptor pathway activity and cytokine marker endpoint expression. Combination protocols should be designed based on receptor system compatibility, with endpoint selection tailored to the specific signaling pathways under investigation and in accordance with institutional laboratory standards.